BIOLOGICAL MARKERS FOR IDENTIFYING PATIENTS FOR TREATMENT WITH VEGF ANTAGONISTS Russian patent published in 2018 - IPC G01N33/50 C12Q1/68 

FIELD: medicine.

SUBSTANCE: proposed group of inventions relates to medicine. Disclosed are a method for determining the probability of a patient with cancer responding to treatment with a VEGF antagonist and a method for selecting therapy for a specific patient with cancer in a population of cancer patients for whom the therapy is suggested. Methods include detecting the expression of at least three genes selected from the group consisting of Alk1, CD34, CD105, CD144, Col4a1, Col4a2, Dll4, EFNB2, EGFL7, ESM1, LAMA4, NG2, Nid2, Notch1, NRP1, NRP2, RGS5, Sema3f, TSP1, VEGFR1, VEGFR2, VEGFR3 and VIM in a biological sample obtained from a patient prior to any administration of the VEGF antagonist to the patient.

EFFECT: proposed group of inventions provides effective means and methods for determining which patients will respond to treatment, and the introduction of effective treatment regimens for such patients.

36 cl, 25 dwg, 4 tbl, 7 ex